Literature DB >> 6248283

The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin.

R Bomford.   

Abstract

Corynebacterium parvum was the only adjuvant of those tested which consistently potentiated delayed-type hypersensitivity (DTH) to sheep red blood cells (SRBC) in the mouse, although this required the antigen-adjuvant mixture to be injected subcutaneously in the footpad rather than the flank. For induction of DTH to ovalbumin (OVA) in the guinea pig, C. parvum and MDP could be substituted for the mycobacteria in FCA. C. parvum was effective in aqueous solution provided that the OVA was absorbed onto alhydrogel. Saponin also potentiated DTH when injected with OVA in aqueous solution. C. parvum was the sole adjuvant of those tested to promote protective cell-mediated immunity (CMI) to M4 fibrosarcoma cells. It is concluded that C. parvum is a promising candidate adjuvant for promoting CMI induction without recourse to a water-in-oil emulsion.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248283      PMCID: PMC1538081     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  [ADJUVANT PROPERTIES OF CORYNEBACTERIUM PARVUM ON ANTIBODY PRODUCTION AND ON THE INDUCTION OF DELAYED HYPERSENSITIVITY TOWARD CONJUGATED PROTEINS].

Authors:  T NEVEU; A BRANELLEC; G BIOZZI
Journal:  Ann Inst Pasteur (Paris)       Date:  1964-05

2.  Corynebacterium parvum as an adjuvant for Trypanosoma cruzi epimastigote vaccines: a comparison with saponin and Bordetella pertussis.

Authors:  R Bomford; N McHardy
Journal:  Parasitology       Date:  1979-02       Impact factor: 3.234

Review 3.  Cell-mediated and humoral immunity to protozoan infections.

Authors:  J Mauel; R Behin
Journal:  Transplant Rev       Date:  1974

Review 4.  Cell-mediated immunity to tumor cells.

Authors:  R B Herberman
Journal:  Adv Cancer Res       Date:  1974       Impact factor: 6.242

5.  Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells.

Authors:  T E Miller; G B Mackaness; P H Lagrange
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

Review 6.  Cell-mediated immunity in certain parasitic infections.

Authors:  J E Larsh; N F Weatherly
Journal:  Curr Top Microbiol Immunol       Date:  1974       Impact factor: 4.291

7.  Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines.

Authors:  K Dalsgaard
Journal:  Arch Gesamte Virusforsch       Date:  1974

8.  Problems in leishmaniasis related to immunology.

Authors:  P C Garnham; J H Humphrey
Journal:  Curr Top Microbiol Immunol       Date:  1969       Impact factor: 4.291

Review 9.  Role of adjuvants in the production of delayed hypersensitivity.

Authors:  R G White
Journal:  Br Med Bull       Date:  1967-01       Impact factor: 4.291

10.  Studies on antibody production. IV. The role of a wax fraction of Mycobacterium tuberculosis in adjuvant emulsions on the production of antibody to egg albumin.

Authors:  R G WHITE; A H COONS; J M CONNOLLY
Journal:  J Exp Med       Date:  1955-07-01       Impact factor: 14.307

View more
  28 in total

1.  The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin.

Authors:  J M Brewer; J Alexander
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

Review 2.  Where are we in the quest for vaccines for malaria?

Authors:  W A Siddiqui
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

3.  Adjuvants et stimulants de l'immunité: propriétés immunorégulatrices du muramyl-dipeptide, des corynébactéries anaérobies et du diéthyldithiocarbamate de sodium.

Authors:  D Archambault; G Morin
Journal:  Can Vet J       Date:  1988-01       Impact factor: 1.008

4.  Synergistic effects of locally administered cytostatic drugs and a surfactant on the development of delayed-type hypersensitivity to keyhole limpet haemocyanin in mice.

Authors:  J Limpens; R J Scheper
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

5.  Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation.

Authors:  J W Mannhalter; H O Neychev; G J Zlabinger; R Ahmad; M M Eibl
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

6.  Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle.

Authors:  D M Lidgate; R C Fu; N E Byars; L C Foster; J S Fleitman
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

7.  Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis.

Authors:  L P Kahl; R Lelchuk; C A Scott; J Beesley
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

8.  Airway response to electrical field stimulation in sensitized inbred mice. Passive transfer of increased responsiveness with peribronchial lymph nodes.

Authors:  G L Larsen; H Renz; J E Loader; K L Bradley; E W Gelfand
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

9.  Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.

Authors:  L Holten-Andersen; T M Doherty; K S Korsholm; P Andersen
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 10.  ProtEx technology for the generation of novel therapeutic cancer vaccines.

Authors:  Rich-Henry Schabowsky; Rajesh K Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S Yolcu; Haval Shirwan
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.